S200: Ibrutinib Versus Placebo in Patients With Asymptomatic, Treatment-Naïve Early Stage Chronic Lymphocytic Leukemia (Cll): Final Results of the Phase 3, Double-Blind, Placebo-Controlled Cll12 Trial

Abstract

We previously demonstrated that early intervention with ibrutinib lead to longer event-free survival in a subgroup of patients with early stage CLL. However, the results did not justify changing the current standard of care as survival analysis was pending.